Pfizer and BioNTech reach agreement to supply EU with 200 million doses of BNT162b2 mRNA-based vaccine candidate against SARS-CoV-2

Vaccine doses for Europe will be produced in BioNTech’s German manufacturing sites, as well as in Pfizer’s manufacturing site in Belgium. If vaccine receives approval from EMA, doses will be ordered by EU Member States who have elected to receive vaccine as part of this agreement

Biospace Inc.